A phase II study of single agent OSI-7904L in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)

被引：0
|
作者：
Hough, B.
Posner, M.
Chung, C.
Hainsworth, J.
Horan, J.
Chick, J.
Gibson, M. K.
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] OSI Pharmaceut, Oxford, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17005
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Degardin, M
    Bastit, P
    Rolland, F
    Armand, JP
    Chevallier, B
    VanGlabbeke, M
    Boudillet, J
    Tresca, P
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 843 - 843
  • [2] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
    Gilbert, J.
    Dang, T.
    Cmelak, A.
    Shyr, Y.
    Netterville, J.
    Burkey, B.
    Chung, C. H.
    Ikpeazu, E.
    Murphy, B. A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2007, 1 : 59 - 63
  • [4] Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Varadarajan, Prakash
    Kotsakis, Athanasios Panayotis
    Martin, Daniel
    Gutkind, Jorge Silvio
    Gibson, Michael K.
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
    Limaye, Sewanti
    Riley, Sarah
    Zhao, Sihai
    O'Neill, Anne
    Posner, Marshall
    Adkins, Douglas
    Jaffa, Zachary
    Clark, John
    Haddad, Robert
    ORAL ONCOLOGY, 2013, 49 (08) : 835 - 841
  • [6] Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN).
    Rhoades, CA
    Kraut, E
    Schuller, D
    Zhang, Y
    Chan, K
    Lang, K
    Eng, C
    Grever, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
  • [7] Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Zenda, Sadamoto
    Onozawa, Yusuke
    Boku, Narikazu
    Fida, Yoshiyuki
    Ebihara, Mitsuru
    Onitsuka, Tetsuro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 477 - 481
  • [8] Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tseng, JE
    Glisson, BS
    Khuri, FR
    Shin, DM
    Myers, JN
    El-Naggar, AK
    Roach, JS
    Ginsberg, LE
    Thall, PF
    Wang, XM
    Teddy, S
    Lawhorn, KN
    Zentgraf, RE
    Steinhaus, GD
    Pluda, JM
    Abbruzzese, JL
    Hong, WK
    Herbst, RS
    CANCER, 2001, 92 (09) : 2364 - 2373
  • [9] A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Lee, Ji Hyun
    Heo, Seong Gu
    Ahn, Beung-Chul
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    Kim, Hye Ryun
    CANCER MEDICINE, 2021, 10 (20): : 7012 - 7020
  • [10] A phase II study of lapatinib (GW572016) in recurrent/metastatic (RIM) squamous cell carcinoma of the head and neck (SCCHN).
    Abidoye, O. O.
    Cohen, E. E.
    Wong, S. J.
    Kozloff, M. F.
    Nattam, S. R.
    Stenson, K. M.
    Blair, E. A.
    Day, S.
    Dancey, J. E.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 297S - 297S
12345